Compare IDEXX Laboratories, Inc. (IDXX) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs SkyWest Inc — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while SkyWest Inc trades at $99.41 (market cap $3.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 11.3× SkyWest Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | SKYW | |
|---|---|---|
Market Cap | $44.48B | $3.94B |
Sector | Health | Technology |
52-Week High | $766.68 | $123.72 |
52-Week Low | $520.87 | $78.40 |
Enterprise Value | $45.38B | $5.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
SkyWest (SKYW) trades at $99.34, up 2.17% today, with a neutral technical signal but bullish moving averages. The stock shows strong profitability with a 10.42% net margin and attractive valuation at a P/E of 9.32. Recent earnings have been mixed, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Analyst consensus is bullish with a $109.33 price target, though news highlights concerns over rising fuel costs impacting airline profits.
The outlook for SKYW is cautiously optimistic, supported by solid fundamentals and analyst buy ratings, but faces headwinds from volatile fuel expenses and competitive pressures. Upside potential exists if the company maintains earnings momentum and manages cost inflation, while downside risks include economic sensitivity and operational challenges in the airline industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
